Brought to you by 
aaiPharma, CIMA enter merger agreement; terminated
04 Nov 2003
Executive Summary
Specialty pharmaceuticals firm aaiPharma is merging with CIMA Labs (develops oral drug delivery technologies) to create a combined company worth approximately $896mm (based on the market averages) that will specialize in developing therapeutics especially for pain management and gastrointestinal conditions.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- OTC, Consumer
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
aaiPharma, CIMA enter merger agreement; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice